Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040729 · ClinicalTrials.gov registry record
Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
NCT00040729: Completed study, sponsored by National Cancer Institute (NCI).
NCT00040729 is a clinical trial that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00040729 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
Study Summary
RATIONALE: Genetic testing for a specific enzyme may help doctors determine whether side effects from or response to chemotherapy are related to a person's genetic makeup. PURPOSE: Genetic trial to determine whether different forms of the UGT1A1 gene are related to the body's ability to break down drugs and to the gastrointestinal side effects seen in patients previously treated with flavopiridol.
Interventions
- GENETIC mutation analysis
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00040729
The ClinicalTrials.gov registry entry for NCT00040729 describes a study currently listed as completed, categorized as an unspecified phase. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mutation analysis is the first listed.
NCT00040729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00040729 about?
NCT00040729 is a clinical study titled "Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C". RATIONALE: Genetic testing for a specific enzyme may help doctors determine whether side effects from or response to chemotherapy are related to a person's genetic makeup. PURPOSE: Genetic trial to determine whether different forms of the UGT1A1 gene are related to the body's ability to break down ...
What is the current status of trial NCT00040729?
This trial is currently completed. The study started on 2002-03.
What interventions are being tested in trial NCT00040729?
The interventions under investigation include: mutation analysis (GENETIC).
Who is sponsoring clinical trial NCT00040729?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.